About Us
Creating the next generation of lateral flow devices
About SwiftDx
Better Informing Healthcare with a Portfolio of Patented Technologies
SwiftDx’s portfolio of patented technologies enable ultra-boosted sensitivity lateral flow diagnostics for diseases which are undetectable with current lateral flow test technology.
SwiftDx has successfully completed the initial technology development phase and is ready to commercialise its DNA detection and eAMP technologies. The company’s first product (the SwiftDx Mycoplasma Detection kit) has been launched and a further products are in development.
Our goal is to better inform patients and healthcare practitioners with a new generation of lateral flow tests.
About us
Our Mission
SwiftDx’s portfolio of patented technologies enable the development of ultra-boosted sensitivity lateral flow diagnostics to detect diseases that might otherwise remain undetected with current lateral flow technology.
Our goal is to use our core technologies to develop a superior range of lateral flow diagnostic tests, compared to existing LFA technology.
Our goal is to use our core technologies to develop a superior range of lateral flow diagnostic tests, compared to existing LFA technology.